Early phase I study of the PARP inhibitor veliparib (ART-888) alone or in combination with carboplatia/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG) Meeting Abstract
| Authors: | Tawbi, H. A. H.; Chu, E.; Lin, Y.; Hyman, D. M.; Goel, S.; Rudek, M. A.; Dowlati, A.; LoRusso, P.; Mulkerin, D.; Chew, H. K.; Kiesel, B.; Pollice, L.; Appleman, L. J.; Puhalla, S.; Stoller, R. G.; Lee, J. J.; Ivy, P.; Beumer, J. H. |
| Abstract Title: | Early phase I study of the PARP inhibitor veliparib (ART-888) alone or in combination with carboplatia/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202837 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.2572 |
| Notes: | Meeting Abstract: 2572 -- Source: Wos |
